Similar articles for PMID: 20222909

Year	Number of Results
2005	2
2006	4
2007	4
2008	9
2009	8
2010	12
2011	3
2012	3
2013	4
2014	3
2015	2
2024	0

1

Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin.

Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, Copetti M, Carretta V, Piazzolla V, Cozzolongo R, Mottola L, Andriulli A. Mangia A, et al. Aliment Pharmacol Ther. 2010 Jun;31(12):1346-53. doi: 10.1111/j.1365-2036.2010.04290.x. Epub 2010 Mar 8. Aliment Pharmacol Ther. 2010. PMID: 20222909 Free article.

2

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.

Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, Oshita M, Mita E, Fukui H, Inada M, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Miyagi T, Hohsui A, Ishida H, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Inoue Y, et al. J Viral Hepat. 2010 May;17(5):336-44. doi: 10.1111/j.1365-2893.2009.01182.x. Epub 2009 Aug 12. J Viral Hepat. 2010. PMID: 19678893

3

[Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].

Li MH, Chen LJ, Qiu GH, Lu Y, Xie Y, Xu DZ. Li MH, et al. Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):497-500. Zhonghua Gan Zang Bing Za Zhi. 2009. PMID: 19912682 Chinese.

4

The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.

Napoli N, Giannelli G, Antonaci A, Antonaci S. Napoli N, et al. J Viral Hepat. 2008 Apr;15(4):300-4. doi: 10.1111/j.1365-2893.2007.00944.x. J Viral Hepat. 2008. PMID: 18307592 Clinical Trial.

5

Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.

Fabris P, Carlotto A, Del Bianco T, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A. Fabris P, et al. Eur J Gastroenterol Hepatol. 2013 Dec;25(12):1396-401. doi: 10.1097/MEG.0b013e328362dc22. Eur J Gastroenterol Hepatol. 2013. PMID: 23743559 Clinical Trial.

6

Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.

Pattullo V, Ravindran NC, Mazzulli T, Wong DK, Heathcote EJ. Pattullo V, et al. J Viral Hepat. 2010 Dec;17(12):834-8. doi: 10.1111/j.1365-2893.2010.01248.x. J Viral Hepat. 2010. PMID: 20196800

7

Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.

Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Yu JW, et al. J Gastroenterol Hepatol. 2007 Jun;22(6):832-6. doi: 10.1111/j.1440-1746.2007.04904.x. J Gastroenterol Hepatol. 2007. PMID: 17565637

8

Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.

Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, Valvano MR, Calvaruso V, Gioffreda D, Milella M, Morisco F, Felder M, Brancaccio G, Fasano M, Gatti P, Tundo P, Barone M, Cozzolongo R, Angelico M, D'Andrea G, Andriulli N, Abate ML, Mazzella G, Gaeta GB, Craxi A, Santantonio T. Andriulli A, et al. J Hepatol. 2014 Jan;60(1):16-21. doi: 10.1016/j.jhep.2013.07.040. Epub 2013 Aug 20. J Hepatol. 2014. PMID: 23973930 Free article.

9

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V. Martin-Carbonero L, et al. AIDS. 2008 Jan 2;22(1):15-21. doi: 10.1097/QAD.0b013e3282f1da99. AIDS. 2008. PMID: 18090387

10

Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.

Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA. Derbala MF, et al. J Viral Hepat. 2008 Aug;15(8):591-9. doi: 10.1111/j.1365-2893.2008.00988.x. Epub 2008 May 14. J Viral Hepat. 2008. PMID: 18482284

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

47 results

Results by year